Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01216956
Other study ID # NIASPAN-C05-36
Secondary ID
Status Completed
Phase N/A
First received October 5, 2010
Last updated October 6, 2010
Start date September 2006
Est. completion date March 2010

Study information

Verified date October 2010
Source Centre de Recherche en Nutrition Humaine Rhone-Alpe
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)France: Institutional Ethical Committee
Study type Interventional

Clinical Trial Summary

Nicotinic acid (Niacin) has been used for many years for the treatment of dyslipidemia. Indeed Niacin decreases triglycerides (TG) and low density lipoprotein cholesterol (LDL-c) but more importantly increases high density lipoprotein cholesterol (HDL-c). Although the drug has been used for so long, its precise mechanism of action remains elusive. The aim of this study was to characterise the metabolic changes induced by 8 week treatment with Niacin in dyslipidemic, overweight patients. The importance of the inhibition of lipolysis on the overall lipid effects of niacin will be studied. In order to get a very comprehensive view of all metabolic activities of niacin, this study will investigate the potential effects of niacin on Glucose metabolism, lipid and lipoprotein turnover, quantitative changes in lipoproteins and key enzymes involved in lipid metabolism.


Description:

24 patients will be included in a double blind placebo controlled cross-over 8 week study comparing placebo to Niaspan (a long release formulation of niacin). In order to prevent any drop out linked to the flushing side effect of niacin, patient will take aspirin (300mg) prior to treatment throughout the study duration. The study will include at start and end of each arm, a full lipoproteins quantification as well as a measure of enzymes involved in lipid metabolism. On day 42 and 56 of each period, after an administration of either placebo or 500mg of immediate release niacin respectively, changes in plasma free fatty acid levels will be measured for 8hours in order to assess potential loss of activity of niacin over time upon chronic treatment with niaspan. Half of the patient will have an exploration of their glucose metabolism using hyperinsulinic clamp technique, whereas in the other half a metabolic turnover study using stable isotopes will focus on their lipoproteins, triglycerides and cholesterol handling. These explorations will be done at the end of each treatment period.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date March 2010
Est. primary completion date June 2009
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Waist circumference > 94cm

- Triglyceride concentration between 150mg/dL and 400mg/dL

- HDL-c < 60mg/dL

- Body mass index: 27 to 35 kg/m²

Exclusion Criteria:

- cancer

- diabetes mellitus

- hepatic, renal or digestive disorder

- hypertension

- chronic medical treatment interfering on lipids parameters

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Drug:
Extended-release nicotinic acid versus placebo
Voluntary men with mixed dyslipidemia and abdominal obesity will receive extended release nicotinic acid. The dose of niaspan will be up-titrated for 3 weeks starting at 500 mg/d in order to reach 2g/d at start of week 4 dose which will be continued until the end of week 8. After a wash-out period of 3 weeks, they will receive placebo for 8 weeks. According to their randomization arm, subjects will receive either in first place placebo followed by extended release nicotinic acid or the opposite.

Locations

Country Name City State
France Centre de Recherche en Nutrition Humaine Nantes

Sponsors (3)

Lead Sponsor Collaborator
Centre de Recherche en Nutrition Humaine Rhone-Alpe GlaxoSmithKline, Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evolution of non-esterified fatty acid and triglycerides concentrations over time Twelve hours after ingestion of chronic treatment, measures of non esterified fatty acid and triglycerides concentrations were carried out during 480 minutes to assess acute and chronic treatment effect on lipolysis and on triglyceride concentration.
To appreciate both acute and chronic effects, subjects received medicinal supplements in addition to their chronic treatment:
On day 42, 500 mg of placebo to assess chronic nicotinic acid effect versus placebo effect
On day 56, 500 mg of immediate-release nicotinic acid (INA) to assess acute versus chronic nicotinic acid effect.
After 42 and 56 days of placebo or nicotinic acid treatment No
Secondary Insulin sensitivity after treatment Euglycemic Hyperinsulinemic clamp with glucose tracer infusion After 53 days of placebo or nicotinic acid treatment No
Secondary Lipoproteins metabolism Stable Isotopic tracer infusion (d3-leucine, 13C-acétate, d5-glycerol) After 53 days of placebo or nicotinic acid treatment No
Secondary Lipid profile Measure of lipoproteins (VLDL, IDL, LDL, HDL) - characterization of lipoprotein's subfraction Measure of enzymatic activity of cholesteryl ester transfer protein (CETP), phospholipid transfer protein (PLTP) and lecithin cholesterol acyl transferase (LCAT) Before and after placebo or nicotinic acid treatment No
See also
  Status Clinical Trial Phase
Completed NCT03458741 - How is Glycogen Supercompensation Regulated in Human Skeletal Muscle N/A
Recruiting NCT06042517 - Mechanisms of Ultrasound Neuromodulation Effects in Diabetes N/A
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Completed NCT03689738 - Effects of Potato Resistant Starch Intake on Insulin Sensitivity, Related Metabolic Markers and Satiety N/A
Recruiting NCT04195165 - The Effect of Sitting and Moderate Exercise on Plasma Insulin and Glucose Responses to an Oral Glucose Tolerance Test N/A
Recruiting NCT05441982 - Saccharin and Acesulfame Potassium Consumption and Glucose Homeostasis in Older Adults With Prediabetes N/A
Terminated NCT03325933 - Resistance Training and Cardiometabolic Health N/A
Recruiting NCT05791968 - Blood Donation Could Improve Insulin Sensitivity N/A
Suspended NCT03240978 - Exercise Intervention for the Prevention of Prediabetes in Overweight Chinese N/A
Completed NCT02700698 - Mitochondrial Function in Circulating Cells and Muscle Tissue
Completed NCT02913079 - The Acute Impact of Sit-stand Desks on Post-meal Blood Sugar Levels N/A
Recruiting NCT01972113 - Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study) N/A
Completed NCT02058914 - Effects of Sugar Sweetened Beverage on Metabolic Health in Male and Female Adolescents N/A
Enrolling by invitation NCT02192684 - Obesity, Sleep Apnea, and Insulin Resistance N/A
Completed NCT00936130 - Bariatric Surgery and Weight Loss on Energy Metabolism and Insulin Sensitivity N/A
Recruiting NCT05992688 - The Sweet Kids Study (Stevia on Weight and Energy Effect Over Time) N/A
Recruiting NCT04168372 - Fructose: Substrate, Stimulus, or Both? N/A
Recruiting NCT05443347 - Activity, Adiposity, and Appetite in Adolescents 2 Intervention N/A
Terminated NCT04239482 - Nutritional Supplementation and Insulin Sensitivity N/A
Withdrawn NCT03452267 - Insulin Signaling in Skeletal Muscle Phase 2/Phase 3